Long-Term Use of Antibiotics and Risk of Parkinson’s Disease in the Nurses’ Health Study by Natalia Palacios, Éilis J O’Reilly, Michael A. Schwarzschild, Alberto Ascherio

Get full text

Prodromal Parkinson’s disease and subsequent risk of Parkinson’s disease and mortality by Xiao Chen, Yaqi Li, Yun Shen, Michael A. Schwarzschild, Xiang Gao

Get full text

Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. by Sara Cipriani, Cody A Desjardins, Thomas C Burdett, Yuehang Xu, Kui Xu, Michael A Schwarzschild

Get full text

Microglia-dependent neuroprotective effects of 4-octyl itaconate against rotenone-and MPP+-induced neurotoxicity in Parkinson’s disease by Ning Xia, Victoria Madore, Ali Albalakhi, Sonia Lin, Taylor Stimpson, Yuehang Xu, Michael A. Schwarzschild, Rachit Bakshi

Get full text

Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons by Hoang Kieu Chi Ngo, Akriti Srivastava, Hoang Le, Samuel J. Ayer, Grace F. Crotty, Michael A. Schwarzschild, Rachit Bakshi

Get full text

Cognitive function in men with non-motor features of Parkinson’s disease by Katherine C Hughes, Xiang Gao, Michael A Schwarzschild, Alberto Ascherio, Mario H Flores-Torres, Samantha Molsberry, Jae H Kang

Get full text

The STEPWISE study: study protocol for a smartphone-based exercise solution for people with Parkinson’s Disease (randomized controlled trial) by Sabine Schootemeijer, Nienke M. de Vries, Eric A. Macklin, Kit C.B. Roes, Hilde Joosten, Larsson Omberg, Alberto Ascherio, Michael A. Schwarzschild, Bastiaan R. Bloem

Get full text

Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss. by Nikolaus R McFarland, Hemi Dimant, Laura Kibuuka, Darius Ebrahimi-Fakhari, Cody A Desjardins, Karin M Danzer, Michael Danzer, Zhanyun Fan, Michael A Schwarzschild, Warren Hirst, Pamela J McLean

Get full text

Key Modulatory Role of Presynaptic Adenosine A2A Receptors in Cortical Neurotransmission to the Striatal Direct Pathway by César Quiroz, Rafael Luján, Motokazu Uchigashima, Ana Patrícia Simoes, Talia N. Lerner, Janusz Borycz, Anil Kachroo, Paula M. Canas, Marco Orru, Michael A. Schwarzschild, Diane L. Rosin, Anatol C. Kreitzer, Rodrigo A. Cunha, Masahiko Watanabe, Sergi Ferré

Get full text

The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism by Caroline M. Tanner, Steven R. Cummings, Michael A. Schwarzschild, Ethan G. Brown, E. Ray Dorsey, Alberto J. Espay, Nicholas B. Galifianakis, Samuel M. Goldman, Irene Litvan, Nijee Luthra, Nikolaus R. McFarland, Kyle T. Mitchell, David G. Standaert, Douglas C. Bauer, Susan L. Greenspan, James C. Beck, Kenneth W. Lyles

Get full text

Study in Parkinson’s disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial by Charity G. Patterson, Elizabeth Joslin, Alexandra B. Gil, Wendy Spigle, Todd Nemet, Lana Chahine, Cory L. Christiansen, Ed Melanson, Wendy M. Kohrt, Martina Mancini, Deborah Josbeno, Katherine Balfany, Garett Griffith, Mac Kenzie Dunlap, Guillaume Lamotte, Erin Suttman, Danielle Larson, Chantale Branson, Kathleen E. McKee, Li Goelz, Cynthia Poon, Barbara Tilley, Un Jung Kang, Malú Gámez Tansey, Nijee Luthra, Caroline M. Tanner, Jacob M. Haus, Giamila Fantuzzi, Nikolaus R. McFarland, Paulina Gonzalez-Latapi, Tatiana Foroud, Robert Motl, Michael A. Schwarzschild, Tanya Simuni, Kenneth Marek, Anna Naito, Codrin Lungu, Daniel M. Corcos, The SPARX3-PSG Investigators

Get full text